IFC Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.51M Buy
4,904
+7
+0.1% +$7.1K 0.65% 31
2025
Q4
$5.26M Buy
4,897
+206
+4% +$197K 0.77% 25
2025
Q3
$3.58M Sell
4,691
-81
-2% -$60.3K 0.66% 31
2025
Q2
$3.72M Sell
4,772
-70
-1% -$54.4K 0.7% 27
2025
Q1
$4M Buy
4,842
+1,427
+42% +$1.19M 0.83% 27
2024
Q4
$2.64M Buy
+3,415
New +$2.83M 0.57% 37

Other funds holding LLY

IFC Advisors's LLY Position: Q1 2026 in Review

IFC Advisors increased its Eli Lilly (LLY) stake by 0.14% in Q1 2026, buying an estimated $7.1K and bringing the position to 4,904 shares worth $4.51M. The position accounts for 0.65% of the portfolio, ranked #31.

IFC Advisors first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.26M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • IFC Advisors held 4,904 shares of Eli Lilly worth $4.51M as of Q1 2026.
  • IFC Advisors bought 7 Eli Lilly shares in Q1 2026, an estimated $7.1K.
  • Eli Lilly made up 0.65% of IFC Advisors's portfolio in Q1 2026, its #31 holding.
  • IFC Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • IFC Advisors's Eli Lilly position peaked at $5.26M in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on IFC Advisors's 13F filing for Q1 2026, filed 4 May 2026.